Search Results | Blood | American Society of Hematology

1-20 of 2656

2 3 4 5

Sort by

Sort Order Select

Journal Articles

Structural characterisation of a novel GPVI nanobody-complex reveals a biologically active domain-swapped GPVI dimer.

Alexandre Slater, Ying Di, Joanne C Clark, Natalie Jasmin Jooss, Eleyna M Martin, Fawaz Obaidullah Alenazy, Mark R Thomas, Robert AS Ariëns, Andrew B. Herr, Natalie S Poulter, Jonas Emsley, Stephen P. Watson

Blood blood.2020009440.

DOI: https://doi.org/10.1182/blood.2020009440

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

DOI: https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Antonia Lopez-Girona, Courtney G. Havens, Gang Lu, Emily Rychak, Derek Mendy, Bonny Gaffney, Christine Surka, Chin-Chun Lu, Mary Matyskiela, Gody Khambatta, Lilly Wong, Joshua Hansen, Daniel W. Pierce, Brian E. Cathers, James Carmichael

Blood (2019) 134 (Supplement_1): 1812.

DOI: https://doi.org/10.1182/blood-2019-124338

Published: 2019

Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD

Blood (2019) 134 (Supplement_1): 1869.

DOI: https://doi.org/10.1182/blood-2019-121805

Published: 2019

Journal Articles

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Takayuki Sasano, Saki Kushima, Matsushita Yutaka, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1814.

DOI: https://doi.org/10.1182/blood-2019-123619

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

DOI: https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Yuxuan Liu, PhD, Jole Fiorito, PhD, Yulissa Gonzalez, Brian Estrella, PhD, Elisa Calcagno, PhD, Elisa Zuccarello, PhD, Howook Hwang, PhD, Barry Honig, PhD, Shixian Deng, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD, Ottavio Arancio, PhD, Jennifer E Amengual, MD

Blood (2019) 134 (Supplement_1): 4068.

DOI: https://doi.org/10.1182/blood-2019-125983

Published: 2019

Journal Articles

Targeting Hypersumoylation in Mantle Cell Lymphoma

Walter Hanel, MD PhD, Liudmyla Tsyba, PhD, Dennis Huszar, PhD, Alex Prouty, Xiaoli Zhang, PhD, JoBeth Helmig-Mason, Msc, Bethany L Mundy-Bosse, PhD, Youssef Youssef, MD, Samir Parekh, MD, Kami J. Maddocks, MD, Robert A Baiocchi, MD PhD, Lapo Alinari, MD PhD

Blood (2019) 134 (Supplement_1): 4060.

DOI: https://doi.org/10.1182/blood-2019-127363

Published: 2019

Journal Articles

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Artavazd Arumov, BSc, Piumi Y. Liyanage, BS, Asaad Trabolsi, MD, Lingxiao Li, PhD, Evan R. Roberts, BS, Daniel Bilbao, PhD, Roger M. LeBlanc, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 4061.

DOI: https://doi.org/10.1182/blood-2019-122599

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

DOI: https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

Binding of Factor VIII to D'D3 and A2 Domains of Von Willebrand Factor Facilitates Mechanical Unraveling of the A2 Domain

Wenjing Cao, MD,PhD, Wenpeng Cao, Wei Zhang, X. Long Zheng, MD, PhD, Xiaohui (Frank) Zhang, PhD

Blood (2019) 134 (Supplement_1): 95.

DOI: https://doi.org/10.1182/blood-2019-125115

Published: 2019

Journal Articles

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

Mitsuteru Hiwatari, MD PhD, Kentaro Watanabe, MD, Yasuo Kubota, MD, Masahiro Sekiguchi, MD, Junko Takita, MD PhD

Blood (2019) 134 (Supplement_1): 5762.

DOI: https://doi.org/10.1182/blood-2019-130056

Published: 2019

Journal Articles

NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia

Stefania Fiorcari, PhD, Rossana Maffei, PhD, Claudio Giacinto Atene, PhD, Silvia Martinelli, Leonardo Potenza, Mario Luppi, MD, Roberto Marasca, MD

Blood (2019) 134 (Supplement_1): 4280.

DOI: https://doi.org/10.1182/blood-2019-128499

Published: 2019

Journal Articles

The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage

Blood (2019) 134 (Supplement_1): 4219.

DOI: https://doi.org/10.1182/blood-2019-126981

Published: 2019

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

DOI: https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Deokki Eom, BS, Jae Hun Jung, Eun Kyung KIM, PhD, Wolyoung Kim, Qingri Li, Jaehyun Jung, Sohee Im, Yong Dae Shin, Hyaejung Hyun, Joon Seok Park

Blood (2019) 134 (Supplement_1): 4426.

DOI: https://doi.org/10.1182/blood-2019-126839

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

DOI: https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

DOI: https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

David Fruman, PhD, Dennis Juarez, B.S., Grace Diep, Undergraduate, Falisha Nguyen, Undergraduate, Vikas A. Gupta, MD PhD, Lawrence H. Boise, PhD

Blood (2019) 134 (Supplement_1): 4413.

DOI: https://doi.org/10.1182/blood-2019-131218

Published: 2019

Journal Articles

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4414.

DOI: https://doi.org/10.1182/blood-2019-122350

Published: 2019

2 3 4 5

NARROW

Structural characterisation of a novel GPVI nanobody-complex reveals a biologically active domain-swapped GPVI dimer.

CC-92480 Is a Novel Cereblon E3 Ligase Modulator with Enhanced Tumoricidal and Immunomodulatory Activity Against Sensitive and Resistant Multiple Myeloma Cells

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators

Targeting Hypersumoylation in Mantle Cell Lymphoma

Targeted Delivery of Nanocarrier-Conjugated Doxorubicin to Widen the Therapeutic Window of the Most Active Drug in Lymphoma Therapeutics

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Binding of Factor VIII to D'D3 and A2 Domains of Von Willebrand Factor Facilitates Mechanical Unraveling of the A2 Domain

Brefeldin Α Reduces STAT3 Dependent Survival of Acute Leukemia and Neuroblastoma Cells

NOTCH2 Contributes to Venetoclax Resistance in Chronic Lymphocytic Leukemia

The SF3B1 K700E Mutation Induces R-Loop Accumulation and Associated DNA Damage

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Discovery of DWP213388, a Potent ITK and BTK Selective Dual Inhibitor with Excellent Efficacy and Safety, for Treating Gvhd

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Statins Enhance Killing of Multiple Myeloma Cells By the BCL-2 Inhibitor Venetoclax and the MCL-1 Inhibitor S63845

The Preclinical Activities of PTC596, a Novel Tubulin Binding Agent That Down-Regulates BMI1, Alone and in Combination with Bortezomib in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only